CYP2A13 CRISPR/Cas9 KO Plasmid (h): sc-403450
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CYP2A13 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CYP2A13 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CYP2A13 CRISPR/Cas9 KO Plasmid (h) | sc-403450 | 20 µg | $397.00 |
Overview
CYP2A13 encodes a human cytochrome P450 monooxygenase predominantly involved in oxidative metabolism of xenobiotics and endogenous substrates. As part of the phase I drug-metabolizing enzyme network, CYP2A13 contributes to NADPH-dependent electron transfer with cytochrome P450 reductase and catalyzes reactions that influence cellular redox balance and reactive metabolite formation. The gene is highly expressed in respiratory tract tissues and is implicated in the bioactivation and detoxification of inhaled compounds, linking its activity to pathways relevant to pulmonary epithelial stress responses. Variation in CYP2A13 expression or activity has been associated with inter-individual differences in xenobiotic handling and susceptibility to chemical-induced tissue damage, supporting its relevance in toxicology and carcinogenesis research models.
CYP2A13 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CYP2A13 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CYP2A13 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CYP2A13 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CYP2A13 protein expression.
This CRISPR knockout system enables efficient generation of CYP2A13-deficient cell models for investigation of CYP2A13 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CYP2A13 exon(s) critical for CYP2A13 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CYP2A13 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CYP2A13 CRISPR/Cas9 KO Plasmid (h) and CYP2A13 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CYP2A13 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CYP2A13 HDR Plasmid (h) and CYP2A13 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CYP2A13 homology arms to support homology-directed repair at defined CYP2A13 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.